about
North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia researchSubstance use in clinical high risk for psychosis: a review of the literatureNorth American Prodrome Longitudinal Study (NAPLS 2): The Prodromal SymptomsRandomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosisBetween-site reliability of startle prepulse inhibition across two early psychosis consortia.Prescription practices in the treatment of first-episode schizophrenia spectrum disorders: data from the national RAISE-ETP studyPsychotropic medication use in youth at high risk for psychosis: comparison of baseline data from two research cohorts 1998-2005 and 2008-2011Reliability of an fMRI paradigm for emotional processing in a multisite longitudinal study.Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment ProgramHealthy adolescent performance on the MATRICS Consensus Cognitive Battery (MCCB): Developmental data from two samples of volunteers.Social cognition mediates illness-related and cognitive influences on social function in patients with schizophrenia-spectrum disorders.Exercise practices in individuals at clinical high risk of developing psychosis.Sexual dimorphisms and prediction of conversion in the NAPLS psychosis prodromeBinocular depth perception in individuals at clinical high risk for psychosis: no evidence of dysfunctionExploratory analysis of social cognition and neurocognition in individuals at clinical high risk for psychosis.Reliability of functional magnetic resonance imaging activation during working memory in a multi-site study: analysis from the North American Prodrome Longitudinal Study.Impact of substance use on conversion to psychosis in youth at clinical high risk of psychosisFamily-focused treatment for adolescents and young adults at high risk for psychosis: results of a randomized trialNegative symptoms in individuals at clinical high risk of psychosis.Current status specifiers for patients at clinical high risk for psychosis.The relationship of neurocognition and negative symptoms to social and role functioning over time in individuals at clinical high risk in the first phase of the North American Prodrome Longitudinal Study.Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North AmericaAssessment of premorbid function in first-episode schizophrenia: modifications to the Premorbid Adjustment Scale.Movement abnormalities predict transitioning to psychosis in individuals at clinical high risk for psychosis.Whither the attenuated psychosis syndrome?Progressive reduction in cortical thickness as psychosis develops: a multisite longitudinal neuroimaging study of youth at elevated clinical risk.Psychosocial treatments for clinical high risk individuals.Treatment history in the psychosis prodrome: characteristics of the North American Prodrome Longitudinal Study CohortTowards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project.Cognitive functioning in first-episode schizophreniaSubstance use and cognition in early psychosisAt clinical high risk for psychosis: outcome for nonconverters.Predictors of a clinical high risk status among individuals with a family history of psychosis.The content of attenuated psychotic symptoms in those at clinical high risk for psychosis.Premorbid functional development and conversion to psychosis in clinical high-risk youths.Negative symptoms and impaired social functioning predict later psychosis in Latino youth at clinical high risk in the North American prodromal longitudinal studies consortium.Prodromal Symptom Severity Predicts Accelerated Gray Matter Reduction and Third Ventricle Expansion Among Clinically High Risk Youth Developing Psychotic DisordersAltered age-related trajectories of amygdala-prefrontal circuitry in adolescents at clinical high risk for psychosis: a preliminary study.The NAVIGATE Program for First-Episode Psychosis: Rationale, Overview, and Description of Psychosocial Components.The development of the Content of Attenuated Positive Symptoms Codebook for those at clinical high risk of psychosis.
P50
Q22242834-13E00562-A22A-4063-B903-63D94B7FA51CQ26859349-9166D192-4D20-428B-BA31-21D19A67DDC7Q27011767-62861FD5-1A6A-4E1F-8056-ABC57E38BAECQ28237307-891248CC-FE76-492F-BA81-56D5E9D649C1Q30432879-073C34C3-BB6A-4FED-92A0-5121E42F3A01Q30627430-F5A57332-2AE5-4192-A2CD-10CCB2A65C16Q30650589-8CF5ADAF-D759-40CD-B30B-ABC2884A0CFBQ30655449-A906CD35-7E6B-4EE4-BC64-2043419D466EQ30797835-A87D3E1E-456C-42B2-BFE5-F0DBCEC70A55Q31047899-4519B9A5-9E81-4517-9077-6226822FA591Q33563165-78F2054A-5233-4F5C-A112-F330793C65A3Q33639130-308F0893-FAD0-4C5A-A027-8A9F44CE557CQ33711020-05F2AC48-C901-46C7-AAE5-32263E4143A5Q33731722-9D21C282-EC67-4F63-BB77-7DE1370D9E1AQ33775768-BE948D64-7B0A-4CDC-BEA7-E449540E9AA3Q33787381-BB23542A-9413-4D8B-940B-20360A3342A0Q33849637-ED6EE747-08A7-454D-836D-AFC7015014F6Q33954717-6AB28D3C-57CC-467D-863B-B24689BA93BCQ33992721-554FDC48-FF97-42E1-B10C-E55BD4452393Q34123531-9D414EEE-F6AA-4CDA-90BF-F1FB095812D3Q34322953-D987921C-8EB8-4C46-95EE-9509A4B7538CQ34586836-057552D8-19D9-49D9-8BC0-68F7EA287164Q34594685-40D1EF42-BF5D-431D-8C43-238BAFCA0AD2Q34619807-2D94B80E-EB62-45A9-BA04-F9FE72B93DC3Q34645261-5C8F07A9-39CB-48A9-A598-9DB27E835806Q34691699-FACD09FC-00AB-45DD-9F9C-D420FCC0774AQ34701114-B279AC31-14F6-40EA-8716-007E5ED37179Q34727780-46E87ADB-CA04-4F2D-BD80-4D23BD40C18BQ35096541-FEB7B24D-3D05-41A1-86F6-45EAAA5245DCQ35100167-EF3F7CE8-57AE-400A-8E1B-5E94673B3FFEQ35101398-3AFD2A65-DCB0-478D-A54F-2615942DEA73Q35148454-5960D220-103E-4E22-B035-01DCB51D3256Q35168075-5017BAF7-CEBA-4E34-BB0D-B30AE48220CCQ35168090-2E5B4D5E-01A9-4043-859A-F56D158C71CAQ35168098-B2834E7C-FC94-4E44-9B0D-1E6F40D1BFE4Q35185253-57E95E36-1EC8-4D4F-A511-9DB15BFE45B6Q35621468-2A312F53-6D51-4A40-AA1A-278DBB9140DAQ35633176-F1B64C1B-3BB5-46F0-AF73-E8EEA2077777Q35812196-DE923FE4-8E7F-4584-9E47-404BF1AECD21Q35824229-66EBCFAA-421A-4380-BC51-F8625001389F
P50
description
researcher
@en
wetenschapper
@nl
name
Jean Addington
@en
Jean Addington
@nl
type
label
Jean Addington
@en
Jean Addington
@nl
prefLabel
Jean Addington
@en
Jean Addington
@nl
P31
P496
0000-0002-8298-0756